Predictive genomics of adverse events after cardiac surgery

Seminars in Cardiothoracic and Vascular Anesthesia

Volumn 8, Issue 4, 2004, Pages 297-315

  Fox, Amanda A ^b   Shernan, Stanton K ^b   Body, Simon C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ELECTIVE SURGERY; GENOMICS; GRAFT REJECTION; HEART ATRIUM FIBRILLATION; HEART SURGERY; HEART TRANSPLANTATION; HEREDITY; HUMAN; HUMAN GENOME; INFECTION; OUTCOMES RESEARCH; POSTOPERATIVE COMPLICATION; PREDICTION; REVIEW; SURGICAL TECHNIQUE; THROMBOCYTOPENIA; VASCULAR DISEASE;

ATRIAL FIBRILLATION; CARDIAC SURGICAL PROCEDURES; GENOMICS; GENOTYPE; HEART TRANSPLANTATION; HUMANS; INFECTION; MUTATION; PHENOTYPE; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS;

EID: 10044258630     PISSN: 10892532     EISSN: None     Source Type: Journal    
DOI: 10.1177/108925320400800404     Document Type: Review

References (105)

1. Kelton JG, Smith JW, Warkentin TE, et al: Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 83:3232-3239, 1994.
2. Amiral J, Wolf M, Fischer A, et al: Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol 92:954-959, 1996.
3. Warkentin TE, Greinacher A: Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 76:638-648, 2003.
4. Warkentin TE: Heparin-induced thrombocytopenia: A ten-year retrospective. Annu Rev Med 50:129-147, 1999.
5. Carlsson LE, Santoso S, Baurichter G, et al: Heparin-induced thrombocytopenia: New insights into the impact of the FcgammaRIIa-R-H131 polymorphism. Blood 92:1526-1531, 1998.
6. Burgess JK, Lindeman R, Chesterman CN, et al: Single amino acid mutation of Fc gamma receptor is associated with the development of heparin-induced thrombocytopenia. Br J Haematol 91:761-766, 1995.
7. Brandt JT, Isenhart CE, Osborne JM, et al: On the role of platelet Fc gamma RIIa phenotype in heparin-induced thrombocytopenia. Thromb Haemost 74:1564-1572, 1995.
8. Denomme GA, Warkentin TE, Horsewood P, et al: Activation of platelets by sera containing IgG1 heparin-dependent antibodies: An explanation for the predominance of the Fc gammaRIIa "low responder" (his131) gene in patients with heparin-induced thrombocytopenia. J Lab Clin Med 130:278-284, 1997.
9. Arepally G, McKenzie SE, Jiang XM, et al: Fc gamma RIIA H/R 131 polymorphism, subclass-specific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis. Blood 89:370-375, 1997.
10. Carlsson LE, Lubenow N, Blumentritt C, et al: Platelet receptor and clotting factor polymorphisms as genetic risk factors for thromboembolic complications in heparin-induced thrombocytopenia. Pharmacogenetics 13:253-258, 2003.
11. Taylor DO, Edwards LB, Mohacsi PJ, et al: The registry of the International Society for Heart and Lung Transplantation: Twentieth official adult heart transplant report - 2003. J Heart Lung Transplant 22:616-624, 2003.
12. Chollet-Martin S, Depoix JP, Hvass U, et al: Raised plasma levels of tumor necrosis factor in heart allograft rejection. Transplant Proc 22:283-286, 1990.
13. Saadi S, Takahashi T, Holzknecht RA, et al: Pathways to acute humoral rejection. Am J Pathol 164:1073-1080, 2004.
14. Abdallah AN, Cucchi-Mouillot P, Biteau N, et al: Analysis of the polymorphism of the turnour necrosis factor (TNF) gene and promoter and of circulating TNF-alpha levels in heart-transplant patients suffering or not suffering from severe rejection. Eur J Immunogenet 26:249-255, 1999.
15. Awad MR, Webber S, Boyle G, et al: The effect of cytokine gene polymorphisms on pediatric heart allograft outcome. J Heart Lung Transplant 20:625-630, 2001.
16. Azzawi M, Hasleton PS, Turner DM, et al: Tumor necrosis factor-alpha gene polymorphism and death due to acute cellular rejection in a subgroup of heart transplant recipients. Hum Immunol 62:140-142, 2001.
17. Turner DM, Grant SC, Lamb WR, et al: A genetic marker of high TNF-alpha production in heart transplant recipients. Transplantation 60:1113-1117, 1995.
18. Wilson AG, Symons JA, McDowell TL, et al: Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 94:3195-3199, 1997.
19. Majetschak M, Flohe S, Obertacke U, et al: Relation of a TNF gene polymorphism to severe sepsis in trauma patients. Ann Surg 230:207-214, 1999.
20. Holweg CT, Peeters AM, Balk AH, et al: Effect of HLA-DR matching on acute rejection after clinical heart transplantation might be influenced by an IL-2 gene polymorphism. Transplantation 73:1353-1356, 2002.
21. Bijlsma FJ, van der Horst AA, Tilanus MG, et al: No association between transforming growth factor beta gene polymorphism and acute allograft rejection after cardiac transplantation. Transpl Immunol 10:43-47, 2002.
22. Bijlsma FJ, Bruggink AH, Hartman M, et al: No association between IL-10 promoter gene polymorphism and heart failure or rejection following cardiac transplantation. Tissue Antigens 57:151-153, 2001.
23. Bijlsma FJ, vanKuik J, Tilanus MG, et al: Donor interleukin-4 promoter gene polymorphism influences allograft rejection after heart transplantation. J Heart Lung Transplant 21:340-346, 2002.
24. Vassalli G, Gallino A, Weis M, et al: Alloimmunity and nonimmunologic risk factors in cardiac allograft vasculopathy. Eur Heart J 24:1180-1188, 2003.
25. Srivastava R, Keck BM, Bennett LE, et al: The results of cardiac retransplantation: An analysis of the Joint International Society for Heart and Lung Transplantation/United Network for Organ Sharing Thoracic Registry. Transplantation 70:606-612, 2000.
26. Waaga AM, Gasser M, Laskowski I, et al: Mechanisms of chronic rejection. Cuff Opin Immunol 12:517-521, 2000.
27. Blobe GC, Schiemann WP, Lodish HF: Role of transforming growth factor beta in human disease. N Engl J Med 342: 1350-1358, 2000.
28. Aziz T, Hasleton P, Hann AW, et al: Transforming growth factor beta in relation to cardiac allograft vasculopathy after heart transplantation. J Thorac Cardiovasc Surg 119: 700-708, 2000.
29. Densem CG, Hutchinson IV, Cooper A, et al: Polymorphism of the transforming growth factor-beta 1 gene correlates with the development of coronary vasculopathy following cardiac transplantation. J Heart Lung Transplant 19:551-556, 2000.
30. Densem CG, Hutchinson IV, Yonan N, et al: Influence of tumor necrosis factor-alpha gene-308 polymorphism on the development of coronary vasculopathy after cardiac transplantation. J Heart Lung Transplant 20:1265-1273, 2001.
31. Vamvakopoulos JE, Taylor CJ, Green C, et al: Interleukin 1 and chronic rejection: Possible genetic links in human heart allografts. Am J Transplant 2:76-83, 2002.
32. Cunningham DA, Crisp SJ, Barbir M, et al: Donor ACE gene polymorphism: A genetic risk factor for accelerated coronary sclerosis following cardiac transplantation. Eur Heart J 19:319-325, 1998.
33. Elstein E, Huan C: Polymorphisms in genes of angiotensin converting enzyme, angiotensinogen, nitric oxide synthase, and endothelin and their association with cardiac allograft rejection. Transplant Proc 29:2576, 1997.
34. Hoffmeyer S, Burk O, von Richter O, et al: Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Nad Acad Sci USA 97:3473-3478, 2000.
35. Yates CR, Chang C, Kearbey JD, et al: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res 20:1794-1803, 2003.
36. Zheng H, Webber S, Zeevi A, et al: The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Hum Immunol 63:765-770, 2002.
37. Zheng H, Webber S, Zeevi A, et al: Tacrolimus dosing in pediatric heart transplant patients is related to GYP3A5 and MDRI gene polymorphisms. Am J Transplant 3:477-483, 2003.
38. Likosky DS, Leavitt BJ, Marrin CA, et al: Intra- and post-operative predictors of stroke after coronary artery bypass grafting. Ann Thorac Surg 76:428-434; discussion 435-439, 2003.
39. Elahi M, Hadjinikolaou L, Galinanes M: Incidence and clinical consequences of atrial fibrillation within 1 year of first-time isolated coronary bypass surgery. Circulation 108 Suppl 1:II207-II212, 2003.
40. Funk M, Richards SB, Desjardins J, et al: Incidence, timing, symptoms, and risk factors for atrial fibrillation after cardiac surgery. Am J Crit Care 12:424-433; quiz 434-435, 2003.
41. Albahrani MJ, Swaminathan M, Phillips-Bute B, et al: Postcardiac surgery complications: Association of acute renal dysfunction and atrial fibrillation. Anesth Analg 96: 637-643, 2003.
42. Hill LL, Kattapuram M, Hogue CW, Jr.: Management of atrial fibrillation after cardiac surgery - part 1: Pathophysiology and risks. J Cardiothorac Vasc Anesth 16:483-494, 2002.
43. Jayam VK, Flaker GC, Jones JW: Atrial fibrillation after coronary bypass: Etiology and pharmacologic prevention. Cardiovasc Surg 10:351-358, 2002.
44. Hakala T, Pitkanen O, Hippelainen M: Feasibility of predicting the risk of atrial fibrillation after coronary artery bypass surgery with logistic regression model. Scand J Surg 91:339-344, 2002.
45. Kim MH, Deeb GM, Morady F, et al: Effect of postoperative atrial fibrillation on length of stay after cardiac surgery (The Postoperative Atrial Fibrillation in Cardiac Surgery study [PACS(2)]. Am J Cardiol 87:881-885, 2001.
46. Wu ZK, Iivainen T, Pehkonen E, et al: Fibrillation in patients subjected to coronary artery bypass grafting. J Thorac Cardiovasc Surg 126:1477-1482, 2003.
47. Murphy GJ, Ascione R, Caputo M, et al: Operative factors that contribute to postoperative atrial fibrillation: Insights from a prospective randomized trial. Card Electrophysiol Rev 7:136-139, 2003.
48. Guo Y, Hu S, Wu Q, et al: Predictors of atrial fibrillation after coronary artery bypass graft surgery. Chin Med J (Engl) 115:232-234, 2002.
49. Svedjeholm R, Hakanson E: Predictors of atrial fibrillation in patients undergoing surgery for ischemic heart disease. Scand Cardiovasc J 34:516-521, 2000.
50. Asher CR, Miller DP, Grimm RA, et al: Analysis of risk factors for development of atrial fibrillation early after cardiac valvular surgery. Am J Cardiol 82:892-895, 1998.
51. Aviles RJ, Martin DO, Apperson-Hansen C, et al: Inflammation as a risk factor for atrial fibrillation. Circulation 108:3006-3010, 2003.
52. Darbar D, Herron KJ, Ballew JD, et al: Familial atrial fibrillation is a genetically heterogeneous disorder. J Am Coll Cardiol 41:2185-2192, 2003.
53. Chen YH, Xu SJ, Bendahhou S, et al: KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science 299: 251-254, 2003.
54. Ellinor PT, Shin JT, Moore RK, et al: Locus for atrial fibrillation maps to chromosome 6q14-16. Circulation 107: 2880-2883, 2003.
55. Gruver EJ, Fatkin D, Dodds GA, et al: Familial hypertrophic cardiomyopathy and atrial fibrillation caused by Arg663His beta-cardiac myosin heavy chain mutation. Am J Cardiol 83:13H-18H, 1999.
56. Yan WT, Liu ZM, Zhang YR, et al: Clinical study of 9 familial atrial fibrillation cases. Chin Med J (Engl) 96:441-444, 1983.
57. Allessie MA: Is atrial fibrillation sometimes a genetic disease? N Engl J Med 336:950-952, 1997.
58. Brugada R, Tapscott T, Czernuszewicz GZ, et al: Identification of a genetic locus for familial atrial fibrillation. N Engl J Med 336:905-911, 1997.
59. Lai LP, Lin JL, Huang SK: Molecular genetic studies in atrial fibrillation. Cardiology 100:109-113, 2003.
60. Mestroni L: Genomic medicine and atrial fibrillation. J Am Coll Cardiol 41:2193-2196, 2003.
61. Gaudino M, Di Castelnuovo A, Zamparelli R, et al: Genetic control of postoperative systemic inflammatory reaction and pulmonary and renal complications after coronary artery surgery. J Thorac Cardiovasc Surg 126:1107-1112, 2003.
62. Gaudino M, Andreotti F, Zamparelli R, et al: The -174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication? Circulation 108 Suppl II:195-199, 2003.
63. Burzotta F, Iacoviello L, Di Gastelnuovo A, et al: Relation of the -174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization. Am J Cardiol 88:1125-1128, 2001.
64. Brull DJ, Montgomery HE, Sanders J, et al: Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol 21:1458-1463, 2001.
65. Kelberman D, Fife M, Rockman MV, et al: Analysis of common IL-6 promoter SNP variants and the AnTn tract in humans and primates and effects on plasma IL-6 levels following coronary artery bypass graft surgery. Biochim Biophys Acta 1688:160-167, 2004.
66. Gensini F, Padeletti L, Fatini C, et al: Angiotensin-converting enzyme and endothelial nitric oxide synthase polymorphisms in patients with atrial fibrillation. Pacing Clin Electrophysiol 26:295-298, 2003.
67. Lai LP, Tsai CC, Su MJ, et al: Atrial fibrillation is associated with accumulation of aging-related common type mitochondrial DNA deletion mutation in human atrial tissue. Chest 123:539-544, 2003.
68. Troye-Blomberg M: Genetic regulation of malaria infection in humans. Chem Immunol 80:243-252, 2002.
69. Pier GB, Grout M, Zaidi T, et al: Salmonella typhi uses CFTR to enter intestinal epithelial cells. Nature 393:79-82, 1998.
70. Beutler B: Innate immunity: An overview. Mol Immunol 40:845-859, 2004.
71. Yee AM, Phan HM, Zuniga R, et al: Association between FcgammaRIIa-R131 allotype and bacteremic pneumococcal pneumonia. Clin Infect Dis 30:25-28, 2000.
72. Wunderink RG, Waterer GW: Genetics of sepsis and pneumonia. Curr Opin Crit Care 9:384-389, 2003.
73. Wunderink RG, Waterer GW, Cantor RM, et al: Tumor necrosis factor gene polymorphisms and the variable presentation and outcome of community-acquired pneumonia. Chest 121:87S, 2002.
74. Schaaf BM, Boehmke F, Esnaashari H, et al: Pneumococcal septic shock is associated with the interleukin-10-1082 gene promoter polymorphism. Am J Respir Crit Care Med 168:476-480, 2003.
75. Arnalich F, Lopez-Maderuelo D, Codoceo R, et al: Interleukin-1 receptor antagonist gene polymorphism and mortality in patients with severe sepsis. Clin Exp Immunol 127:331-336, 2002.
76. Heesen M, Kunz D, Bachmann-Mennenga B, et al: Linkage disequilibrium between tumor necrosis factor (TNF)-alpha-308 G/A promoter and TNF-beta Ncol polymorphisms: Association with TNF-alpha response of granulocytes to endotoxin stimulation. Crit Care Med 31:211-214, 2003.
77. Stuber F, Petersen M, Bokelmann F, et al: A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med 24:381-384, 1996.
78. Mira JP, Cariou A, Grall F, et al: Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: A multicenter study. JAMA 282: 561-568, 1999.
79. Zhang D, Li J, Jiang ZW, et al: Association of two polymorphisms of tumor necrosis factor gene with acute severe pancreatitis. J Surg Res 112:138-143, 2003.
80. Nadel S, Newport MJ, Booy R, et al: Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease. J Infect Dis 174:878-880, 1996.
81. Waterer GW, Quasney MW, Cantor RM, et al: Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. Am J Respir Crit Care Med 163:1599-1604, 2001.
82. Dianliang Z, Jieshou L, Zhiwei J, et al: Association of plasma levels of tumor necrosis factor (TNF)-alpha and its soluble receptors, two polymorphisms of the TNF gene, with acute severe pancreatitis and early septic shock due to it. Pancreas 26:339-343, 2003.
83. Zhang DL, Li JS, Jiang ZW, et al: Association of two polymorphisms of tumor necrosis factor gene with acute biliary pancreatitis. World J Gastroenterol 9:824-828, 2003.
84. Tang GJ, Huang SL, Yien HW, et al: Tumor necrosis factor gene polymorphism and septic shock in surgical infection. Crit Care Med 28:2733-2736, 2000.
85. Calvano JE, Um JY, Agnese DM, et al: Influence of the TNF-alpha and TNF-beta polymorphisms upon infectious risk and outcome in surgical intensive care patients. Surg Infect (Larchmt) 4:163-169, 2003.
86. Fang XM, Schroder S, Hoeft A, et al: Comparison of two polymorphisms of the interleukin-1 gene family: Interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. Crit Care Med 27:1330-1334, 1999.
87. Stuber F, Udalova IA, Book M, et al: -308 tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and is unrelated to lipopolysaccharide inducibility of the human TNF promoter. J Inflamm 46:42-50, 1995.
88. Tomasdottir H, Hjartarson H, Ricksten A, et al: Tumor necrosis factor gene polymorphism is associated with enhanced systemic inflammatory response and increased cardiopulmonary morbidity after cardiac surgery. Anesth Analg 97:944-949, 2003.
89. Read RG, Cannings C, Naylor SC, et al: Variation within genes encoding interleukin-1 and the interleukin-1 receptor antagonist influence the severity of meningococcal disease. Ann Intern Med 138:534-541, 2003.
90. Read RG, Camp NJ, di Giovine FS, et al: An interleukin-1 genotype is associated with fatal outcome of meningococcal disease. J Infect Dis 182:1557-1560, 2000.
91. Tarlow JK, Blakemore AI, Lennard A, et al: Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 91:403-404, 1993.
92. Ma P, Chen D, Pan J, et al: Genomic polymorphism within interleukin-1 family cytokines influences the outcome of septic patients. Crit Care Med 30:1046-1050, 2002.
93. Harding D, Dhamrait S, Millar A, et al: Is interleukin-6-174 genotype associated with the development of septicemia in preterm infants? Pediatrics 112:800-803, 2003.
94. Schluter B, Raufhake C, Erren M, et al: Effect of the interleukin-6 promoter polymorphism (-174 G/C) on the incidence and outcome of sepsis. Crit Care Med 30:32-37, 2002.
95. Treszl A, Kocsis I, Szathmari M, et al: Genetic variants of TNF-[FG12]a, IL-1beta, IL-4 receptor [FG12]a-chain, IL-6 and IL10 genes are not risk factors for sepsis in low-birth-weight infants. Biol Neonate 83:241-245, 2003.
96. Baldini M, Lohman IC, Halonen M, et al: A Polymorphism* in the 5′ flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol 20:976-983, 1999.
97. Gibot S, Cariou A, Drouet L, et al: Association between a genomic polymorphism within the CD14 locus and septic shock susceptibility and mortality rate. Crit Care Med 30: 969-973, 2002.
98. Hubacek JA, Stuber F, Frohlich D, et al: The common functional C(-159)T polymorphism within the promoter region of the lipopolysaccharide receptor CD14 is not associated with sepsis development or mortality. Genes Immun 1:405-407, 2000.
99. Arbour NC, Lorenz E, Schutte BC, et al: TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 25:187-191, 2000.
100. Schwartz DA: TLR4 and LPS hyporesponsiveness in humans. Int J Hyg Environ Health 205:221-227, 2002.
101. Erridge C, Stewart J, Poxton IR: Monocytes heterozygous for the Asp299GIy and Thr399IIe mutations in the Toll-like receptor 4 gene show no deficit in lipopolysaccharide signalling. J Exp Med 197:1787-1791, 2003.
102. Schippers EF, van't Veer C, van Voorden S, et al: TNFalpha promoter, Nod2 and toll-like receptor-4 polymorphisms and the in vivo and ex vivo response to endotoxin. Cytokine 26:16-24, 2004.
103. Feterowski C, Emmanuilidis K, Miethke T, et al: Effects of functional Toll-like receptor-4 mutations on the immune response to human and experimental sepsis. Immunology 109:426-431, 2003.
104. Lorenz E, Mira JP, Frees KL, et al: Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 162:1028-1032, 2002.
105. Read RC, Pullin J, Gregory S, et al: A functional polymorphism of toll-like receptor 4 is not associated with likelihood or severity of meningococcal disease. J Infect Dis 184:640-642, 2001.